Sorafenib Alleviates Inflammatory Signaling of Tumor Microenvironment in Precancerous Lung Injuries

• Autores principales: Betul Cicek (Autor), Ahmet Hacimuftuoglu (Autor), Mehmet Kuzucu (Autor), Ahmet Cetin (Autor), Yesim Yeni (Autor), Sidika Genc (Autor), Serkan Yildirim (Autor), Ismail Bolat (Autor), Mecit Kantarci (Autor), Mustafa Gul (Autor), Serhat Hayme (Autor), Dimitris Matthaios (Autor), Dimitra P. Vageli (Autor), Sotirios G. Doukas (Autor), Aristidis Tsatsakis (Autor), Ali Taghizadehghalehjoughi (Autor)
• Formato: Libro
• Publicado: MDPI AG, 2023-02-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

According to population-based studies, lung cancer is the prominent reason for cancer-related mortality worldwide in males and is also rising in females at an alarming rate. Sorafenib (SOR), which is approved for the treatment of hepatocellular carcinoma and renal cell carcinoma, is a multitargeted...